Institutional members access full text with Ovid®

Share this article on:

Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia

Souza, Renan P.a b c; Remington, Garya b; Meltzer, Herbert Y.d; Lieberman, Jeffrey A.e; Kennedy, James L.a b; Wong, Albert H.C.a c

International Clinical Psychopharmacology: September 2010 - Volume 25 - Issue 5 - p 264-269
doi: 10.1097/YIC.0b013e32833a5ff9
Original Articles

Phosphodiesterase 4B (PDE4B) has been evaluated as a genetic risk factor for schizophrenia. Selective PDE4 inhibitor drugs have antipsychotic-like effects and reduce tardive dyskinesia-like movements in animal models. We investigated whether PDE4B genetic variants are associated with antipsychotic-induced tardive dyskinesia incidence and severity in schizophrenia patients. Our sample consisted of 169 Caucasian patients taking typical antipsychotic medication for at least 1 year. We found two PDE4B gene variants to be nominally associated with tardive dyskinesia (rs1338719 and rs7528545) in the overall population and two other variants nominally associated with the presence of tardive dyskinesia and severity in female patients (rs1890196 and rs783036). None of these results survived correction for multiple testing. Overall, our results do not support a genetic association between tardive dyskinesia and PDE4B.

aNeurogenetics Section, Centre for Addiction and Mental Health

bDepartment of Psychiatry, University of Toronto

cDepartment of Pharmacology, University of Toronto, Toronto, Ontario, Canada

dPsychiatric Hospital, Vanderbilt University, Nashville, Tennessee

eNew York State Psychiatric Institute, Columbia University Medical Centre, New York, USA

Correspondence to Dr. James L. Kennedy and Dr Albert H.C. Wong, Centre for Addiction and Mental Health, 250 College Street, Toronto, Canada M5T 1R8

Tel: +141 653 58501; fax: +141 697 94666;


Received 21 January 2010 Accepted 29 March 2010

© 2010 Lippincott Williams & Wilkins, Inc.